MALT Lymphoma Trial Fails to Establish Best Frontline Therapy

According to published results of the IESLG-19 trial, adding rituximab to chlorambucil in patients with mucosa-associated lymphoid tissue (MALT) lymphoma did not improve overall survival, despite demonstrating reasonable response rates.

This is a disappointment since the IESLG-19 trial (Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma) was initially launched in an effort to lead to a consensus regarding front-line therapy in MALT lymphoma patients by comparing chlorambucil alone versus chlorambucil plus rituximab in patients not previously given any systemic therapy.

About the Trial

The trial positioned 113 patients in the chlorambucil arm and 114 patients in the combination arm. A third arm was eventually conceived that consisted solely of rituximab, but these findings relate only to the first two arms.

With a median follow-up duration of 62 months, event-free survival (EFS) was 50 percent in the monotherapy arm and 68 percent in the combination arm. Overall response rates were 87 percent for the monotherapy arm and 90 percent for the combination arm. Patients in the combination arm had a higher complete remission rate (78 percent vs 65 percent). A five-year overall survival rate of 89 percent was reported in both arms.

Researchers concluded, "Both treatments were active; the better response rate and EFS obtained with the addition of rituximab did not translate into improved OS."

Source: JCO

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap